TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22338129

Group type: EXPERIMENTAL
Intervention: Laparoscopic presacral neurectomy (LPN) in addition to conventional laparoscopic resection of endometriosis lesions
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional laparoscopic resection of endometriosis lesions
Number of subjects: 64
Study: 19694853

Group type: EXPERIMENTAL
Intervention: Supportive counselling programme
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ordinary counselling
Number of subjects: 42
Study: 17524958

Group type: EXPERIMENTAL
Intervention: ANCOVA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RM with Kenward and Roger's adjustment
Number of subjects: 0

Group type: COMPARATOR
Intervention: RM
Number of subjects: 0
Study: 17287298

Group type: EXPERIMENTAL
Intervention: Intrabronchial administration of recombinant surfactant protein C-based surfactant preparation (Venticute)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Surfactant treatment (Venticute)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Supplementation of Venticute with synthetic neutral lipid preparation
Number of subjects: 31
Study: 10936812

Group type: EXPERIMENTAL
Intervention: Use of sorbents in continuous plasma filtration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonspecific simultaneous removal of several mediators of the inflammatory cascade
Number of subjects: 0
Study: 8791050

Group type: EXPERIMENTAL
Intervention: Cisplatin 60 mg/m2 i.v. and epirubicin 60 mg/m2 i.v. every 3 weeks for six cycles, with estramustine phosphate at 10 mg/kg p.o. in two divided daily doses during chemotherapy and until progression.
Number of subjects: 28
Study: 1619006

Group type: EXPERIMENTAL
Intervention: Intranasal octreotide 2000 micrograms
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intranasal octreotide 1000 micrograms
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intranasal octreotide 500 micrograms
Number of subjects: 15

Group type: COMPARATOR
Intervention: Subcutaneous octreotide 100 micrograms
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intranasal octreotide (all doses)
Number of subjects: 15
Study: 6095549

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg/die
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cimetidine 2000 mg/die
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cimetidine 2000 mg/die + Pirenzepine 2 X 10 mg/die
Number of subjects: 12
Study: 30137455

Group type: EXPERIMENTAL
Intervention: 35% CO2‐enriched air
Number of subjects: 90

Group type: COMPARATOR
Intervention: Compressed room air
Number of subjects: 90
Study: 30138422

Group type: EXPERIMENTAL
Intervention: T‐piece
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: PSV
Number of subjects: 190
Study: 27139523

Group type: EXPERIMENTAL
Intervention: Reduced-intensity treatment with liberalized goals for serum phosphorus and parathyroid hormone (PTH)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 16
Study: 24401752

Group type: EXPERIMENTAL
Intervention: Social franchising program training community educators and supplying ORS plus zinc
Number of subjects: 3605

Group type: COMPARATOR
Intervention: Standard ORS access
Number of subjects: 3605
Study: 23168103

Group type: EXPERIMENTAL
Intervention: Standardized Patient (SP) training
Number of subjects: 27

Group type: COMPARATOR
Intervention: No SP training (Control)
Number of subjects: 27
Study: 19965852

Group type: EXPERIMENTAL
Intervention: Small-vessel VaD
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Large-vessel VaD
Number of subjects: 484
Study: 18728024

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Number of subjects: 0
Study: 15811142

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg three times daily)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo (three times daily)
Number of subjects: 339
Study: 12876240

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (Rebif) treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups (IFNbeta and placebo)
Number of subjects: 38
Study: 10390006

Group type: EXPERIMENTAL
Intervention: Standard care plus relaxation training and imagery
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Imagery ratings
Number of subjects: 96
Study: 8529290

Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 62

Group type: COMPARATOR
Intervention: Metoclopramide cocktail
Number of subjects: 62
Study: 1906432

Group type: EXPERIMENTAL
Intervention: Cibenzoline (260 mg/day and 320 mg/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Flecainide (200 mg/day and 300 mg/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Flecainide (long-term treatment after conversion)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cibenzoline (long-term treatment after conversion)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cibenzoline and Flecainide
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 31
Study: 31162588

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNSs) to pregnant women until 6 mo postpartum and child LNSs from 6-24 mo of age (LNS-LNS)
Number of subjects: 4011

Group type: EXPERIMENTAL
Intervention: Iron and folic acid (IFA) until 3 mo postpartum and child LNSs at 6-24 mo (IFA-LNS)
Number of subjects: 4011

Group type: EXPERIMENTAL
Intervention: Iron and folic acid (IFA) and child micronutrient powder (MNP) at 6-24 mo (IFA-MNP)
Number of subjects: 4011

Group type: COMPARATOR
Intervention: Iron and folic acid (IFA) and no child supplement (IFA-Control)
Number of subjects: 4011
Study: 29199503

Group type: EXPERIMENTAL
Intervention: SMART Arm with outcome-triggered electrical stimulation and usual therapy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SMART Arm alone and usual therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: usual therapy
Number of subjects: 50
Study: 25243819

Group type: EXPERIMENTAL
Intervention: Laparoscopic-guidance (LG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Skilled instructor (SI)
Number of subjects: 40
Study: 24934070

Group type: EXPERIMENTAL
Intervention: Diet soda (200 ml with aspartame and acesulfame potassium)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Regular soda (200 ml without sweetener)
Number of subjects: 80
Study: 21367921

Group type: EXPERIMENTAL
Intervention: Desmopressin (10 and 25 μg melt doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desmopressin (100 μg melt dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desmopressin (50-100 μg melt) for men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desmopressin (25 μg melt) for women
Number of subjects: 0
Study: 20422814

Group type: EXPERIMENTAL
Intervention: Epoietin alpha intravenously
Number of subjects: 60

Group type: COMPARATOR
Intervention: Epoietin beta intravenously (Control group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Epoietin beta subcutaneously (Control group B)
Number of subjects: 60
Study: 17173900

Group type: EXPERIMENTAL
Intervention: Triptorelin and tibolone cotreatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no treatment specified)
Number of subjects: 30
Study: 15058789

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention program targeting general practice staff lasting 21 months
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 62
Study: 11865169

Group type: EXPERIMENTAL
Intervention: Stroke unit
Number of subjects: 2269

Group type: COMPARATOR
Intervention: General medical wards
Number of subjects: 2269
Study: 9834809

Group type: EXPERIMENTAL
Intervention: Genius thermometer
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Thermoscan thermometer
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Quickthermo thermometer
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Thermopit thermometer
Number of subjects: 10
Study: 7666796

Group type: EXPERIMENTAL
Intervention: GHRH1-29NH2 (1 micrograms/kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: GHRP-2 (1 microgram/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: GHRH1-29NH2
Number of subjects: 15

Group type: COMPARATOR
Intervention: GHRP-2
Number of subjects: 15
Study: 2774261

Group type: EXPERIMENTAL
Intervention: Active airway humidification using an MR450 Servo airway heater and humidifier set at 37 degrees C (n = 10)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Passive airway humidification using the Humid‐Vent 1 heat and moisture exchanger (n = 8)
Number of subjects: 27

Group type: COMPARATOR
Intervention: No airway humidification and heating (control, n = 9)
Number of subjects: 27
Study: 773301

Group type: EXPERIMENTAL
Intervention: Intravenous gentamicin by bolus administration (3 to 5 min)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Slow infusion of gentamicin (2 h)
Number of subjects: 63
Study: 31583436

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily with chemotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Metformin with chemotherapy
Number of subjects: 100
Study: 28183276

Group type: EXPERIMENTAL
Intervention: Peginterferon beta‐1a every 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed treatment
Number of subjects: 0
Study: 25454291

Group type: EXPERIMENTAL
Intervention: Tensioned taping applied perpendicular to the UT fibers
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Non-tensioned taping
Number of subjects: 42

Group type: COMPARATOR
Intervention: No taping
Number of subjects: 42
Study: 23726373

Group type: EXPERIMENTAL
Intervention: 50 μg ghrelin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 21366475

Group type: EXPERIMENTAL
Intervention: Long-acting injectable risperidone (25 to 50 mg every two weeks)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Oral antipsychotics (psychiatrist's choice)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Long-acting injectable risperidone
Number of subjects: 369
Study: 19695629

Group type: EXPERIMENTAL
Intervention: Active transcutaneous electrical nerve stimulation for 4 weeks (2 hours daily)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham transcutaneous electrical nerve stimulation for 4 weeks (2 hours daily)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Active transcutaneous electrical nerve stimulation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham transcutaneous electrical nerve stimulation
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 27
Study: 16856215

Group type: COMPARATOR
Intervention: Venlafaxine XR
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 93
Study: 12631158

Group type: EXPERIMENTAL
Intervention: Professional prophylaxis only
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Deep scaling
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Surgical periodontal flap surgery and scaling
Number of subjects: 120

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 120
Study: 11208401

Group type: EXPERIMENTAL
Intervention: Minimally invasive techniques for saphenous vein harvesting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional longitudinal incision for saphenous vein harvesting
Number of subjects: 0
Study: 9392698

Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg twice a day)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 8268431

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cryoanalgesia
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intrapleural analgesia
Number of subjects: 45
Study: 3813145

Group type: EXPERIMENTAL
Intervention: 15 mg bupivacaine 0.375% without glucose (Group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 15 mg bupivacaine 0.375% with 2.5% glucose (Group II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 15 mg bupivacaine 0.375% with 7.5% glucose (Group III)
Number of subjects: 60
Study: 29738790

Group type: EXPERIMENTAL
Intervention: Narrow- or wide-pulse NMES
Number of subjects: 30
Study: 26860217

Group type: EXPERIMENTAL
Intervention: ENABLE early palliative care intervention
Number of subjects: 207

Group type: COMPARATOR
Intervention: ENABLE delayed palliative care intervention
Number of subjects: 207
Study: 24344872

Group type: EXPERIMENTAL
Intervention: T/iDHT/E2 (Testosterone gel with dutasteride)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: T/DHT/E2 (Testosterone gel alone)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57

Group type: COMPARATOR
Intervention: T/DHT/iE2 (Testosterone gel with anastrazole)
Number of subjects: 57
Study: 21503628

Group type: EXPERIMENTAL
Intervention: Forest therapy camp program
Number of subjects: 92

Group type: COMPARATOR
Intervention: Normal daily routines (Control)
Number of subjects: 92
Study: 20110084

Group type: EXPERIMENTAL
Intervention: duloxetine (60 mg/day)
Number of subjects: 250
Study: 18757768

Group type: EXPERIMENTAL
Intervention: Major depression
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Minor depression
Number of subjects: 281
Study: 16249960

Group type: EXPERIMENTAL
Intervention: Citicoline (1,000 mg/die intramuscularly) for 2 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Citicoline (1,000 mg/die intramuscularly) during additional 2-month periods for a total of 16 periods in 8 years
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 2 months
Number of subjects: 30
Study: 12132610

Group type: EXPERIMENTAL
Intervention: Zinc picolinate (29 mg orally by capsule 3 times a day for 3 months)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 10745565

Group type: EXPERIMENTAL
Intervention: AngioJet therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urokinase
Number of subjects: 0
Study: 7601299

Group type: EXPERIMENTAL
Intervention: 100 mg oral sumatriptan
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study: 2082492

Group type: EXPERIMENTAL
Intervention: Intravenous dipyridamole
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Oral dipyridamole
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Dipyridamole (oral and intravenous)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 98
Study: 7006663

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Intermittent melphalan
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Melphalan with prednisone
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Good renal function with haemoglobin above 100 g/l
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Renal function groups (good, intermediate, poor)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Haemoglobin level at presentation
Number of subjects: 372
Study: 31900227

Group type: EXPERIMENTAL
Intervention: Endoscopic radiofrequency ablation (ERFA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional percutaneous radiofrequency ablation (Control)
Number of subjects: 60
Study: 31584031

Group type: EXPERIMENTAL
Intervention: Dry brushing
Number of subjects: 43

Group type: COMPARATOR
Intervention: Wet brushing
Number of subjects: 43
Study: 30012187

Group type: EXPERIMENTAL
Intervention: Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low-molecular-weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Placebo: routinely used intraocular infusion with balanced salt solution during routine PPV
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Intraoperative adjuvant application of 5-FU and LMWH
Number of subjects: 560
Study: 25662759

Group type: EXPERIMENTAL
Intervention: Marjoram tea
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo tea
Number of subjects: 25
Study: 24361739

Group type: EXPERIMENTAL
Intervention: theta transcranial alternating current stimulation (tACS) applied to left parietal and right parietal areas
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: theta transcranial alternating current stimulation (tACS) applied to left parietal area
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: theta transcranial alternating current stimulation (tACS) applied to right parietal area
Number of subjects: 36

Group type: COMPARATOR
Intervention: sham tACS
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: theta transcranial alternating current stimulation (tACS) applied to left frontal area
Number of subjects: 36
Study: 22706833

Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive behavioral therapy (T-CBT)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Face-to-face cognitive behavioral therapy (CBT)
Number of subjects: 325
Study: 20157695

Group type: EXPERIMENTAL
Intervention: Framingham risk equations
Number of subjects: 7502

Group type: EXPERIMENTAL
Intervention: UKPDS risk equations
Number of subjects: 7502

Group type: EXPERIMENTAL
Intervention: UKPDS and Framingham risk equations
Number of subjects: 7502
Study: 17442998

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/d) with cisplatin and gemcitabine
Number of subjects: 1172

Group type: COMPARATOR
Intervention: Placebo with cisplatin and gemcitabine
Number of subjects: 1172
Study: 16082603

Group type: EXPERIMENTAL
Intervention: Patient self-testing (PST) with testing every week
Number of subjects: 400

Group type: COMPARATOR
Intervention: High quality anticoagulation management (HQACM) with testing every 4 weeks
Number of subjects: 400
Study: 11507928

Group type: EXPERIMENTAL
Intervention: Sodium hexametaphosphate dentifrice (7%)
Number of subjects: 551

Group type: COMPARATOR
Intervention: Regular sodium fluoride dentifrice
Number of subjects: 551

Group type: COMPARATOR
Intervention: Triclosan/copolymer dentifrice
Number of subjects: 551
Study: 10633886

Group type: EXPERIMENTAL
Intervention: Enamel matrix proteins (EMD)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 14
Study: 8607400

Group type: EXPERIMENTAL
Intervention: Vitamins C and E (600 mg/day, orally for 14 days)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional treatment only (control group)
Number of subjects: 61
Study: 1663053

Group type: EXPERIMENTAL
Intervention: MgCl2
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1 microgram/d of 1-alpha (OH)D
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined 1-alpha (OH)D and MgCl2
Number of subjects: 10
Study: 7165010

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 5.5 gm/m2 daily for 30 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 19
Study: 30712729

Group type: EXPERIMENTAL
Intervention: MiYoga mindfulness yoga program
Number of subjects: 42
Study: 28626020

Group type: EXPERIMENTAL
Intervention: 2000 IU Vitamin D 3 supplementation
Number of subjects: 42
Study: 27023825

Group type: EXPERIMENTAL
Intervention: Percutaneous Cortical Bone Trajectory (pCBT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional Percutaneous Pedicle Screw (PPS)
Number of subjects: 40
Study: 25475489

Group type: EXPERIMENTAL
Intervention: Family-based education plus usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 23386016

Group type: EXPERIMENTAL
Intervention: Computer‐Assisted Insulin Protocol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Leuven Protocol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 60
Study: 20457167

Group type: EXPERIMENTAL
Intervention: 40 mg single oral dose of propranolol (beta-noradrenergic antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonsocial feedback (green vs. red color signals)
Number of subjects: 0
Study: 17600459

Group type: EXPERIMENTAL
Intervention: Usual care plus an educational intervention on risk-factor management
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 50
Study: 15710304

Group type: EXPERIMENTAL
Intervention: Formal Elements Art Therapy Scale task
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Free Drawing
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Outline
Number of subjects: 60
Study: 11845369

Group type: EXPERIMENTAL
Intervention: Active (Ga-As) laser treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo laser treatment
Number of subjects: 40
Study: 10412580

Group type: EXPERIMENTAL
Intervention: Cytological method at the presurgery stage
Number of subjects: 200
Study: 7623991

Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (ACEi) - 10 mg enalapril o.d.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combination of LPD and ACEi
Number of subjects: 14
Study: 2187519

Group type: EXPERIMENTAL
Intervention: Duplex scanning
Number of subjects: 29

Group type: COMPARATOR
Intervention: Arteriography
Number of subjects: 29
Study: 7069070

Group type: EXPERIMENTAL
Intervention: Nasal breathing
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral breathing
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 14
Study: 31465842

Group type: EXPERIMENTAL
Intervention: Pharmacological rhythm control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Membrane-active antiarrhythmic drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stricter rate control (target rate <80/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Catheter ablation of long-standing AF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term oral anticoagulation with non-vitamin K-antagonist oral anticoagulants
Number of subjects: 0
Study: 30910488

Group type: EXPERIMENTAL
Intervention: Noninvasive interactive neurostimulation (NIN) therapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 61
Study: 28987768

Group type: EXPERIMENTAL
Intervention: pembrolizumab Q2W
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: pembrolizumab Q3W
Number of subjects: 776

Group type: COMPARATOR
Intervention: ipilimumab
Number of subjects: 776